As both the ErbB family of receptors and Met are promising molecular targets for therapy of NSCLC, and with evidence for functional interactions of these receptors, we have explored the possibility that combined targeting of Met and one or more ErbB family members may have therapeutic promise. Here, MET is linked to non-small cell lung carcinoma.